Copyright
©The Author(s) 2024.
World J Methodol. Sep 20, 2024; 14(3): 91058
Published online Sep 20, 2024. doi: 10.5662/wjm.v14.i3.91058
Published online Sep 20, 2024. doi: 10.5662/wjm.v14.i3.91058
Table 1 Liver stiffness measurement cutoffs
Severity of fibrosis | METAVIR stages | LSM in kPa |
Normal | F0-F1 | 2 - 7 |
Mild fibrosis | F2 | 7.1-11 |
Moderate fibrosis | F3 | 11.1-21 |
Severe fibrosis | F4 | > 21 |
Table 2 Biological variables for non-fibrotic, mild fibrotic, moderate fibrotic and severe fibrotic hepatitis C virus cases
Indices | No fibrosis0 | Mild fibrosis1 | Moderate fibrosis2 | Severe fibrosis3 | P value | ||||
Median | IQR | Median | IQR | Median | IQR | Median | IQR | ||
Routine investigations | |||||||||
Viral load | 112792 | 56721.5-131470.5 | 308255 | 231893.25-424659.75 | 1050000 | 696516.5-1334612.5 | 4956005 | 3170155.25-9357337 | 0.000a |
Hb | 13.2 | 11.35-15 | 13 | 11.07-14.7 | 13 | 10.65-14 | 12.95 | 10.95-13.4 | 0.674 |
INR | 1 | 1-1.1 | 1.1 | 1.0175-1.3 | 1.1 | 1-1.185 | 1.09 | 1-1.1775 | 0.478 |
TSP | 6.9 | 6.55-7.155 | 6.9 | 6.6-7.2 | 7.1 | 6.65-7.72 | 7 | 6.55-7.2 | 0.683 |
Albumin | 3.9 | 3.55-4.5 | 3.8 | 3.5-4.175 | 4.1 | 3.55-4.3 | 3.85 | 3.375-4.3 | 0.849 |
Bilirubin | 0.68 | 0.4-0.7 | 0.7 | 0.5-0.895 | 0.7 | 0.4-0.95 | 0.8 | 0.475-1 | 0.488 |
AST | 43 | 31.5-63 | 53.5 | 30.5-92.75 | 97 | 70.5-115.5 | 108.5 | 62.5-172.5 | 0.000a |
ALT | 50 | 36-77 | 60 | 40.25-93.3 | 92 | 56-175.5 | 106.5 | 85.25-151 | 0.030a |
ALP | 85 | 77.5-88 | 82 | 78.25-88 | 102 | 97.5-131 | 150 | 129.5-168 | 0.000a |
TLC | 8800 | 7700-9450 | 8050 | 6750-9075 | 7200 | 6600-8500 | 7200 | 6500-7725 | 0.000a |
Plt count | 216 | 158-279.5 | 195 | 138.75-235 | 160 | 111.5-210 | 130 | 102-160.25 | 0.000a |
Special investigations | |||||||||
Fibronectin | 98 | 89.82-101.25 | 118 | 113.4-126.57 | 147 | 138.75-154 | 204.5 | 188.975-222.25 | 0.000a |
AAR | 0.83 | 0.64-1.08 | 0.86 | 0.71-1.21 | 0.89 | 0.724-1.26 | 1.82 | 1.159-4.37 | 0.704 |
APRI | 0.52 | 0.33-0.69 | 0.6 | 0.495-1.84 | 1.67 | 0.95-2.291 | 1.82 | 1.159-4.37 | 0.000a |
FIB-4 | 1 | 0.63-1.29 | 1.44 | 0.98-2.29 | 2.52 | 2.04-3.918 | 3.77 | 2.68-6.6 | 0.000a |
Table 3 Correlation and significance with respect to liver stiffness measurement
Indices | R | P value |
Routine investigations | ||
Viral load | 0.663 | 0.000a |
Hb | -0.169 | 0.092 |
INR | 0.041 | 0.688 |
TSP | 0.081 | 0.425 |
Albumin | -0.06 | 0.552 |
Bilirubin | 0.149 | 0.14 |
AST | 0.428 | 0.000a |
ALT | 0.3 | 0.000a |
ALP | 0.747 | 0.000a |
TLC | -0.391 | 0.000a |
Plt count | -0.473 | 0.000a |
Special investigations | ||
Serum fibronectin | 0.929 | 0.000a |
AAR | 0.127 | 0.207 |
APRI | 0.574 | 0.000a |
FIB-4 | 0.586 | 0.000a |
Table 4 Diagnostic accuracy for fibronectin, aspartate aminotransferase to platelet ratio index, and fibrosis-4
Indices | S. Fibronectin, % | APRI, % | FIB-4, % |
Fibrosis | |||
Sensitivity | 98.70 | 73.30 | 73.30 |
Specificity | 100 | 88 | 96 |
Youdens index | 0.987 | 0.613 | 0.693 |
AUROC | 1 | 0.829 | 0.85 |
LR+ | > 10 | < 10 | > 10 |
LR- | 0.013 | 0.303 | 0.277 |
Mild fibrosis | |||
Sensitivity | 100 | 45.80 | 45.80 |
Specificity | 96 | 88 | 96 |
Youdens index | 0.96 | 0.338 | 0.418 |
AUROC | 0.999 | 0.672 | 0.725 |
LR+ | > 10 | < 10 | > 10 |
LR- | 0 | 0.615 | 0.564 |
Moderate fibrosis | |||
Sensitivity | 92.20 | 80.40 | 82.40 |
Specificity | 100 | 77.60 | 85.70 |
Youdens index | 0.922 | 0.579 | 0.681 |
AUROC | 0.993 | 0.836 | 0.853 |
LR+ | > 10 | < 10 | < 10 |
LR- | 0.0784 | 0.252 | 0.205 |
Severe fibrosis | |||
Sensitivity | 96.20 | 84.60 | 92.30 |
Specificity | 98.60 | 62.20 | 71.60 |
Youdens index | 0.948 | 0.468 | 0.639 |
AUROC | 0.922 | 0.796 | 0.835 |
LR+ | > 10 | < 10 | < 10 |
LR- | 0.038 | 0.247 | 0.107 |
Table 5 Conditional probability table for liver fibrosis severity with respect to fibronectin
Fibronectin | Fibronectin < 150, % | Fibronectin 150-200, % | Fibronectin > 200, % |
LF severity (0) | 37 | 1 | 1 |
LF severity (1) | 36 | 1 | 1 |
LF severity (2) | 25 | 42 | 1 |
LF severity (3) | 2 | 57 | 98 |
Table 6 Conditional probability table for liver fibrosis severity with respect to special investigations
Fibronectin | Fibronectin < 150, % | Fibronectin 150-200, % | Fibronectin > 200, % |
AAR | AAR (< 1) | AAR (1) | AAR (> 1) |
APRI | APRI (< 2) | APRI (2-3) | APRI (> 3) |
FIB-4 | FIB-4 (< 2) | FIB-4 (2-4) | FIB-4 (> 4) |
LF severity (0) | 59 | 0 | 0 |
LF severity (1) | 31 | 0 | 0 |
LF severity (2) | 8 | 77 | 0 |
LF severity (3) | 2 | 23 | 100 |
- Citation: Kaur N, Goyal G, Garg R, Tapasvi C, Demirbaga U. Ensemble for evaluating diagnostic efficacy of non-invasive indices in predicting liver fibrosis in untreated hepatitis C virus population. World J Methodol 2024; 14(3): 91058
- URL: https://www.wjgnet.com/2222-0682/full/v14/i3/91058.htm
- DOI: https://dx.doi.org/10.5662/wjm.v14.i3.91058